← Back to Clinical Trials
Recruiting NCT06168266

NCT06168266 Effects of Eccentric Exercise Training in Patients With COPD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06168266
Status Recruiting
Phase
Sponsor Fu Jen Catholic University
Condition COPD
Study Type INTERVENTIONAL
Enrollment 170 participants
Start Date 2023-12-13
Primary Completion 2027-10-30

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Eccentric bikeconventional group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 170 participants in total. It began in 2023-12-13 with a primary completion date of 2027-10-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to design eccentric exercise strategies for COPD patients to comprehensively improve their cardiopulmonary/muscular fitness, immune and hemorheological functions, and quality of life, thereby improving the prognosis of their disease.

Eligibility Criteria

Inclusion Criteria: * Having undergone pulmonary rehabilitation for more than 3 months * Sign the written informed consent form * FEV1/FVC \< 0.70 * Approval for exercise training granted by a specialist physician's assessment * Specialist physician's approval for exercise training Exclusion Criteria: * Existing of tracheostomy * Those who use oxygen therapy or ventilator at home * Severe heart failure (NYHA III-IV) * Neuromuscular disease * Acute exacerbation within the past three months * Those who are unable to cooperate with the cardiopulmonary exercise test * Taking anticoagulant medications * Other conditions restricting exercise for over a year * Recent or planned significant cardiovascular surgery or intervention * Current or planned pregnancy within the next year * Planned heart transplant within the next six months * Heart failure due to uncorrectable valvular heart disease, congenital heart disease or obstructive cardiomyopathy * Inadequate ICD settings for exercise heart rate * Other exercise contraindications: unstable angina, uncontrolled blood pressure, orthostatic hypotension with symptoms, severe aortic stenosis, acute discomfort or fever, uncontrolled arrhythmias, uncompensated heart failure, acute pericarditis or myocarditis, recent thrombosis or thrombophlebitis, resting ST-segment deviation, uncontrolled diabetes, etc.

Contact & Investigator

Central Contact

Ke-Yun Chao, PhD

✉ C00152@mail.fjuh.fju.edu.tw

📞 +886905301879

Principal Investigator

Ke-Yun Chao, PhD

PRINCIPAL INVESTIGATOR

Fu Jen Catholic University Hospital

Frequently Asked Questions

Who can join the NCT06168266 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 80 Years, studying COPD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06168266 currently recruiting?

Yes, NCT06168266 is actively recruiting participants. Contact the research team at C00152@mail.fjuh.fju.edu.tw for enrollment information.

Where is the NCT06168266 trial being conducted?

This trial is being conducted at New Taipei City, Taiwan.

Who is sponsoring the NCT06168266 clinical trial?

NCT06168266 is sponsored by Fu Jen Catholic University. The principal investigator is Ke-Yun Chao, PhD at Fu Jen Catholic University Hospital. The trial plans to enroll 170 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology